VR Adviser LLC acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,295,319 shares of the company's stock, valued at approximately $37,735,000. Upstream Bio makes up approximately 2.6% of VR Adviser LLC's portfolio, making the stock its 14th biggest holding. VR Adviser LLC owned about 4.28% of Upstream Bio as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of UPB. Moody Aldrich Partners LLC purchased a new position in shares of Upstream Bio during the 4th quarter valued at about $1,229,000. Legal & General Group Plc purchased a new stake in Upstream Bio in the 4th quarter worth approximately $28,000. Barclays PLC acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $445,000. MetLife Investment Management LLC acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $181,000. Finally, Corebridge Financial Inc. purchased a new position in shares of Upstream Bio during the 4th quarter valued at approximately $142,000.
Upstream Bio Trading Up 4.7%
UPB opened at $9.05 on Tuesday. The firm has a fifty day moving average price of $8.06 and a 200 day moving average price of $12.75. Upstream Bio, Inc. has a 1 year low of $5.14 and a 1 year high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. On average, research analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Want to see what other hedge funds are holding UPB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Upstream Bio, Inc. (NASDAQ:UPB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
